Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction program

Affiliation auteurs!!!! Error affiliation !!!!
TitreLong-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction program
Type de publicationJournal Article
Year of Publication2020
AuteursDanchin N, Farnier M, Zeller M, Puymirat E, Cottin Y, Belle L, Lemesle G, Cayla G, Ohlmann P, Jacquemin L, Perret T, Angoulvant D, Albert F, Ferrieres J, Schiele F, Simon T, Investigators FAST-MI
JournalJOURNAL OF CLINICAL LIPIDOLOGY
Volume14
Pagination352+
Date PublishedMAY-JUN
Type of ArticleArticle
ISSN1933-2874
Mots-clésacute myocardial infarction, Familial hypercholesterolemia, long-term outcome
Résumé

{BACKGROUND: Patients with familial hypercholesterolemia (FH) are prone to develop acute myocardial infarction (AMI) at a younger age. OBJECTIVES: The aim of the present study was to assess 5-year outcomes after AMI according to the presence of FH in a large multicenter cohort of patients. METHODS: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction consists of nationwide surveys recruiting patients over a 1- to 2-month period every 5 years. Patients recruited in 2005 and 2010 were followed up to 5 years. RESULTS: Of 5147 patients discharged alive and in whom FH status could be assessed, 2.8% had probable/definite FH, using an adapted Dutch Lipid Clinic score. They were 12 years younger, on average, than non-FH patients. Before adjustment, their 5-year survival and event-free survival did not differ from non-FH patients. After adjustment, however, both mortality (hazard ratio [HR] 1.82, 95% confidence interval [CI] 1.15-2.89; P = .011) and the combined endpoint of death, AMI, or stroke (HR 2.22, 95% CI: 1.51-3.26; P < .001) were higher in FH patients. The higher risk in FH patients was also present in patients receiving high-intensity lipid-lowering therapy at discharge: adjusted HR for mortality 2.29, 95% CI: 1.18 to 4.47

DOI10.1016/j.jacl.2020.03.008